Related Experiment Video

Updated: Apr 15, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

[Statins diabetogenicity: are all the same? state of art]

Joan Rius Tarruella1, Jesús Millán Núñez-Cortés2, Juan Pedro-Botet3

  • 1Medical Affairs Cardiovascular Area, ESTEVE, Barcelona, España.

Clinica E Investigacion En Arteriosclerosis : Publicacion Oficial De La Sociedad Espanola De Arteriosclerosis
|April 4, 2015
PubMed

Insights

Statins can increase type 2 diabetes risk. Pitavastatin, however, significantly decreased new-onset type 2 diabetes incidence in a study, suggesting it as a safer cardiovascular prevention option.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Pharmacology

Background:

  • Statins are crucial for cardiovascular prevention, including in type 2 diabetes mellitus (T2DM) patients.
  • However, statin use can increase T2DM risk, especially in predisposed individuals.
  • Different statins exhibit varying glucose-raising or diabetogenic capacities.

Purpose of the Study:

  • To evaluate the incidence of new-onset T2DM with statin therapy.
  • To compare the diabetogenic effects of different statins.
  • To assess pitavastatin's effect on de novo T2DM in patients with abnormal glucose tolerance.

Main Methods:

  • Meta-analysis of controlled clinical trials for high-quality evidence.
  • Focus on studies systematically evaluating T2DM incidence.
  • The J-PREDICT trial specifically investigated pitavastatin versus lifestyle modification.

Main Results:

  • Pitavastatin was associated with a significant decrease in de novo T2DM incidence.
  • This effect was observed when compared to lifestyle modification alone.
  • Preliminary results suggest pitavastatin may have a favorable glucose profile.

Conclusions:

  • Pitavastatin may be a suitable alternative for cardiovascular risk reduction in T2DM patients or those at risk.
  • It potentially offers a reduced risk of developing new-onset T2DM compared to other statins or lifestyle changes alone.
  • Further research is needed to confirm these findings across diverse populations.
Keywords:
Cardiovascular diseaseDiabetes mellitus tipo 2DisglicemiaDysglycemiaEnfermedad cardiovascularEstatinasHbA1cPrevenciónPreventionStatinsType 2 diabetes mellitus

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.3K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
989
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
605
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
909